

# ASIA PACIFIC INFERTILITY TESTING AND TREATMENT MARKET FORECAST 2018-2026

<https://marketpublishers.com/r/A57AC6784CAEN.html>

Date: January 2018

Pages: 0

Price: US\$ 1,250.00 (Single User License)

ID: A57AC6784CAEN

## Abstracts

### KEY FINDINGS

The Asia-Pacific infertility testing and treatment market is slated to progress with the highest CAGR of 7.06% by the year 2026. The revenue generated by the market in the year 2017 amounted to \$5169.2 million. By the end of the forecast period of 2018-2026, the market is expected to reach a worth of \$9585.23 million.

### MARKET INSIGHTS

Growing male infertility, high middle-class income, increasing number of couples opting for surrogacy and booming medical tourism are some of the key trends witnessed by the Asia-Pacific infertility testing and treatment market. The South Korean market is predicted to grow with the highest CAGR over the projected years. Rising medical tourism in South Korea due to the low cost of technology in the region acts as a major driver for this market. The other key markets in Asia-Pacific region are Thailand, India, Japan, Taiwan, China and Singapore.

### COMPETITIVE INSIGHTS

Few of the established companies in this region include Endo Pharmaceuticals, Natera Inc, Centogene, Quest Diagnostic, LabCorp, Roche, Irvine Scientific, Phosphorus Diagnostics, Genea, Alere, Illumina Inc, Thermo Fisher Scientific Inc, Andrology Solutions, Halotech DNA, and Claritas.

## Contents

### **1. RESEARCH SCOPE**

- 1.1. STUDY GOALS
- 1.2. SCOPE OF THE MARKET STUDY
- 1.3. WHO WILL FIND THIS REPORT USEFUL?
- 1.4. STUDY AND FORECASTING YEARS

### **2. RESEARCH METHODOLOGY**

- 2.1. SOURCES OF DATA
  - 2.1.1. SECONDARY DATA
  - 2.1.2. PRIMARY DATA
- 2.2. TOP DOWN APPROACH
- 2.3. BOTTOM-UP APPROACH
- 2.4. DATA TRIANGULATION

### **3. EXECUTIVE SUMMARY**

- 3.1. MARKET SUMMARY
- 3.2. KEY FINDINGS
  - 3.2.1. ASIA PACIFIC IS THE FASTEST GROWING REGION IN THE INFERTILITY MARKET
  - 3.2.2. IVF DOMINATES THE FEMALE TREATMENT MARKET
  - 3.2.3. OXIDATIVE STRESS ANALYSIS IS THE FASTEST GROWING MALE INFERTILITY TESTING MARKET

### **4. MARKET OVERVIEW**

- 4.1. MARKET DEFINITION
- 4.2. MARKET DRIVERS AND IMPACT
  - 4.2.1. RISE IN INFERTILITY AND TREATMENT AWARENESS
  - 4.2.2. MEDICAL TOURISM IN FERTILITY TREATMENTS
  - 4.2.3. SURROGACY LAWS ARE GETTING MORE DEFINED
  - 4.2.4. HEALTHCARE ADVANCES HAVE FINETUNED FERTILITY TREATMENT
  - 4.2.5. INCREASING EFFECTIVENESS OF TREATMENTS
  - 4.2.6. HEALTHIER DONOR EGGS
  - 4.2.7. INTRODUCTION OF NEW TESTING DEVICES

#### 4.3. RESTRAINTS AND IMPACT

4.3.1. TREATMENT PROCEDURE OUT OF REACH TO MANY DUE TO COSTS INVOLVED

4.3.2. COUNTRY-WISE REGULATORY ISSUES

#### 4.4. MARKET OPPORTUNITIES

4.4.1. REDUCING THE COST OF TREATMENT TO MAKE IT MORE ACCESSIBLE

4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS

4.4.3. DIY TESTING INCREASING ACCESS AND REDUCING COST

#### 4.5. MARKET CHALLENGES

4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN

4.5.2. PERILS OF MULTIPLE PREGNANCIES

4.5.3. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE FOR INFERTILITY TREATMENTS

4.5.3.1. DIET AND SUPPLEMENTS

4.5.3.2. ACUPUNCTURE

4.5.3.3. THERAPY

4.5.3.4. QIGONG

### 5. INFERTILITY CAUSES

#### 5.1. CAUSES OF MALE INFERTILITY

5.1.1. ABNORMALITY IN THE SPERM

5.1.2. ENVIRONMENTAL FACTORS

5.1.3. POOR HEALTH AND LIFESTYLE

#### 5.2. CAUSES OF FEMALE INFERTILITY

5.2.1. OVULATION DISORDERS

5.2.2. DAMAGE TO FALLOPIAN TUBES

#### 5.3. MORAL QUESTIONS

### 6. MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

#### 6.1. MARKET BY MALE INFERTILITY TESTING

6.1.1. DNA FRAGMENTATION

6.1.2. OXIDATIVE STRESS ANALYSIS

6.1.3. SPERM PENETRATION ASSAY

6.1.4. COMPUTER ASSISTED SEMEN ANALYSIS (CASA)

6.1.5. SPERM AGGLUTINATION

6.1.6. MICROSCOPIC EXAMINATION

#### 6.1.7. OTHERS

### 6.2. MARKET BY MALE INFERTILITY TREATMENT

#### 6.2.1. VASOVASOSTOMY AND VASOEPIDIDYMOSTOMY (VASECTOMY REVERSAL)

#### 6.2.2. SPERM RETRIEVAL TREATMENT

#### 6.2.3. MICROSURGICAL SPERM ASPIRATION (MESA)

#### 6.2.4. TESTICULAR SPERM EXTRACTION (TESE)

#### 6.2.5. VARICOCELE REPAIRS

#### 6.2.6. ASSISTED REPRODUCTIVE TECHNIQUES (ART)

#### 6.2.7. INTRAUTERINE INSEMINATION (IUI)

#### 6.2.8. IN VITRO FERTILIZATION (IVF)

#### 6.2.9. INTRACYTOPLASMIC SPERM INJECTION (ICSI)

## 7. FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

### 7.1. MARKET BY FEMALE INFERTILITY TESTING

#### 7.1.1. OVULATION TESTING

#### 7.1.2. HYSTEROSALPINGOGRAPHY

#### 7.1.3. LAPAROSCOPY

#### 7.1.4. TRANSVAGINAL ULTRASOUND

#### 7.1.5. OVARIAN RESERVE TESTING

#### 7.1.6. HORMONAL LEVEL TESTING

#### 7.1.7. OTHERS (GENETIC TESTING)

### 7.2. MARKET BY FEMALE INFERTILITY TREATMENT

#### 7.2.1. IN VITRO FERTILIZATION

#### 7.2.2. INTRAUTERINE INSEMINATION (IUI)

#### 7.2.3. DRUG AND HORMONE THERAPIES

## 8. ASIA PACIFIC INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 (\$ MILLION)

### 8.1. FERTILITY AND SURGICAL CENTERS

### 8.2. HOSPITALS AND RESEARCH LABORATORIES

### 8.3. CRYOBANKS

## 9. KEY ANALYTICS

### 9.1. PORTERS 5 FORCE MODEL

- 9.1.1. THREAT OF NEW ENTRANTS
- 9.1.2. THREAT OF SUBSTITUTE PRODUCTS
- 9.1.3. BARGAINING POWER OF BUYERS
- 9.1.4. BARGAINING POWER OF SUPPLIERS
- 9.1.5. INTENSITY OF COMPETITIVE RIVALRY
- 9.2. VALUE CHAIN ANALYSIS
  - 9.2.1. RAW MATERIAL PROCUREMENT
  - 9.2.2. MANUFACTURING
  - 9.2.3. SUPPLY LOGISTICS
  - 9.2.4. DISTRIBUTION CHANNELS
  - 9.2.5. END USERS
- 9.3. KEY BUYING CRITERIA
  - 9.3.1. TREATMENT OPTIONS
  - 9.3.2. QUALITY OF MEDICAL PROCEDURES
  - 9.3.3. PRICE OF TREATMENTS
  - 9.3.4. SHIFT TOWARDS MEDICAL TOURISM
  - 9.3.5. REIMBURSEMENT
- 9.4. REGULATORY FRAMEWORK
- 9.5. KEY TRENDS
  - 9.5.1. MALE INFERTILITY TREATMENT SEGMENT IS RISING
  - 9.5.2. FERTILITY TOURISM- AN IMPORTANT TREND
  - 9.5.3. UPPER MIDDLE INCOME GROUP IS THE KEY TARGET
  - 9.5.4. REGULATORY ENVIRONMENT KEY MARKET ENABLER
  - 9.5.5. MORE COUPLES OPTING FOR SURROGACY
  - 9.5.6. TECHNOLOGY ENABLING THE SUCCESS OF FERTILITY TREATMENTS
- 9.6. VENDOR LANDSCAPE
- 9.7. OPPORTUNITY MATRIX

## **10. KEY ANALYTICS – TESTING MARKET**

- 10.1. PORTER'S 5 FORCE ANALYSIS
  - 10.1.1. THREAT OF NEW ENTRANTS
  - 10.1.2. THREAT OF SUBSTITUTE PRODUCTS
  - 10.1.3. BARGAINING POWER OF BUYERS
  - 10.1.4. BARGAINING POWER OF SUPPLIERS
  - 10.1.5. INTENSITY OF COMPETITIVE RIVALRY
- 10.2. KEY BUYING CRITERIA
- 10.3. VENDOR LANDSCAPE
- 10.4. OPPORTUNITY MATRIX

## **11. ASIA PACIFIC INFERTILITY TESTING AND TREATMENT MARKET COUNTRY ANALYSIS 2018-2026 (\$ MILLION)**

- 11.1. CHINA
- 11.2. INDIA
- 11.3. JAPAN
- 11.4. SOUTH KOREA
- 11.5. REST OF ASIA-PACIFIC

## **12. COMPETITIVE ANALYSIS**

- 12.1. ANDROLOGY SOLUTIONS
  - 12.1.1. OVERVIEW
  - 12.1.2. PRODUCT PORTFOLIO
  - 12.1.3. SCOT ANALYSIS
- 12.2. ENDO PHARMACEUTICALS
  - 12.2.1. OVERVIEW
  - 12.2.2. PRODUCT PORTFOLIO
  - 12.2.3. STRATEGIC MOVES
  - 12.2.4. SCOT ANALYSIS
- 12.3. PROGYNV
  - 12.3.1. OVERVIEW
  - 12.3.2. PRODUCT PORTFOLIO
  - 12.3.3. STRATEGIC MOVES
  - 12.3.4. SCOT ANALYSIS
- 12.4. FERRING PHARMACEUTICALS
  - 12.4.1. OVERVIEW
  - 12.4.2. PRODUCT PORTFOLIO
  - 12.4.3. STRATEGIC MOVES
  - 12.4.4. SCOT ANALYSIS
- 12.5. GENEV
  - 12.5.1. OVERVIEW
  - 12.5.2. PRODUCT PORTFOLIO
  - 12.5.3. STRATEGIC MOVES
  - 12.5.4. SCOT ANALYSIS
- 12.6. HALOTECH DNA
  - 12.6.1. OVERVIEW
  - 12.6.2. PRODUCT PORTFOLIO

- 12.6.3. STRATEGIC MOVES
- 12.6.4. SCOT ANALYSIS
- 12.7. IRVINE SCIENTIFIC
  - 12.7.1. OVERVIEW
  - 12.7.2. PRODUCT PORTFOLIO
  - 12.7.3. STRATEGIC MOVES
  - 12.7.4. SCOT ANALYSIS
- 12.8. MERCK
  - 12.8.1. OVERVIEW
  - 12.8.2. PRODUCT PORTFOLIO
  - 12.8.3. STRATEGIC MOVES
  - 12.8.4. SCOT ANALYSIS
- 12.9. ORIGIO
  - 12.9.1. OVERVIEW
  - 12.9.2. PRODUCT PORTFOLIO
  - 12.9.3. STRATEGIC MOVES
  - 12.9.4. SCOT ANALYSIS
- 12.10. OVASCIENCE
  - 12.10.1. OVERVIEW
  - 12.10.2. PRODUCT PORTFOLIO
  - 12.10.3. STRATEGIC MOVES
  - 12.10.4. SCOT ANALYSIS
- 12.11. VITROLIFE AB
  - 12.11.1. OVERVIEW
  - 12.11.2. PRODUCT PORTFOLIO
  - 12.11.3. STRATEGIC MOVES
  - 12.11.4. SCOT ANALYSIS
- 12.12. THERMO FISHER SCIENTIFIC INC
  - 12.12.1. OVERVIEW
  - 12.12.2. PRODUCT PORTFOLIO
  - 12.12.3. STRATEGIC MOVES
  - 12.12.4. SCOT ANALYSIS
- 12.13. THE COOPER COMPANIES, INC
  - 12.13.1. OVERVIEW
  - 12.13.2. PRODUCT PORTFOLIO
  - 12.13.3. STRATEGIC MOVES
  - 12.13.4. SCOT ANALYSIS
- 12.14. QUEST DIAGNOSTIC
  - 12.14.1. OVERVIEW

- 12.14.2. PRODUCT PORTFOLIO
- 12.14.3. SCOT ANALYSIS
- 12.14.4. STRATEGIC MOVES
- 12.15. ESCO MICRO PTE. LTD.
- 12.15.1. OVERVIEW
- 12.15.2. PRODUCT PORTFOLIO
- 12.15.3. STRATEGIC MOVES
- 12.15.4. SCOT ANALYSIS
- 12.16. ELUCIGENE
- 12.16.1. OVERVIEW
- 12.16.2. PRODUCT PORTFOLIO
- 12.16.3. SCOT ANALYSIS
- 12.16.4. STRATEGIC INITIATIVE
- 12.17. ALERE
- 12.17.1. OVERVIEW
- 12.17.2. PRODUCT PORTFOLIO
- 12.17.3. SCOT ANALYSIS
- 12.17.4. STRATEGIC INITIATIVE
- 12.18. CELMATRIX
- 12.18.1. OVERVIEW
- 12.18.2. PRODUCT PORTFOLIO
- 12.18.3. SCOT ANALYSIS
- 12.18.4. STRATEGIC INITIATIVE
- 12.19. VERITAS GENETICS
- 12.19.1. OVERVIEW
- 12.19.2. PRODUCT PORTFOLIO
- 12.19.3. SCOT ANALYSIS
- 12.19.4. STRATEGIC INITIATIVE
- 12.20. CLARITAS GENOMICS
- 12.20.1. OVERVIEW
- 12.20.2. PRODUCT PORTFOLIO
- 12.20.3. SCOT ANALYSIS
- 12.20.4. STRATEGIC INITIATIVE
- 12.21. ROCHE
- 12.21.1. OVERVIEW
- 12.21.2. PRODUCT PORTFOLIO
- 12.21.3. SCOT ANALYSIS
- 12.21.4. STRATEGIC INITIATIVE
- 12.22. LABCORP



- 12.22.1. OVERVIEW
- 12.22.2. PRODUCT PORTFOLIO
- 12.22.3. SCOT ANALYSIS
- 12.22.4. STRATEGIC INITIATIVE
- 12.23. AGILENT
  - 12.23.1. OVERVIEW
  - 12.23.2. PRODUCT PORTFOLIO
  - 12.23.3. SCOT ANALYSIS
  - 12.23.4. STRATEGIC INITIATIVE
- 12.24. INTEGRATED GENETICS
  - 12.24.1. OVERVIEW
  - 12.24.2. PRODUCT PORTFOLIO
  - 12.24.3. SCOT ANALYSIS
- 12.25. PHOSPHORUS DIAGNOSTICS
  - 12.25.1. OVERVIEW
  - 12.25.2. PRODUCT PORTFOLIO
  - 12.25.3. SCOT ANALYSIS
  - 12.25.4. STRATEGIC INITIATIVE
- 12.26. CENTOGENE
  - 12.26.1. OVERVIEW
  - 12.26.2. PRODUCT PORTFOLIO
  - 12.26.3. SCOT ANALYSIS
  - 12.26.4. STRATEGIC INITIATIVE
- 12.27. NATERA INC
  - 12.27.1. OVERVIEW
  - 12.27.2. PRODUCT PORTFOLIO
  - 12.27.3. SCOT ANALYSIS
  - 12.27.4. STRATEGIC INITIATIVE
- 12.28. ILLUMINA INC
  - 12.28.1. OVERVIEW
  - 12.28.2. PRODUCT PORTFOLIO
  - 12.28.3. SCOT ANALYSIS
  - 12.28.4. STRATEGIC INITIATIVE

## List Of Tables

### LIST OF TABLES

TABLE 1 ASIA PACIFIC INFERTILITY TESTING AND TREATMENT MARKET BY GENDER 2018-2026 (\$ MILLION)

TABLE 2 AVERAGE COST COMPARISON OF INFERTILITY TREATMENTS

TABLE 3 ASIA PACIFIC MALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

TABLE 4 ASIA PACIFIC MALE INFERTILITY TESTING MARKET 2018-2026(\$MILLION)

TABLE 5 PROS AND CONS OF DNA SHARING METHODS

TABLE 6 ASIA PACIFIC FEMALE INFERTILITY TESTING AND TREATMENT MARKET 2018-2026 (\$ MILLION)

TABLE 7 ASIA PACIFIC FEMALE INFERTILITY TESTING MARKET 2018-2026 (\$MILLION)

TABLE 8 ASIA PACIFIC FEMALE INFERTILITY TREATMENT MARKET 2018-2026 (\$ MILLION)

TABLE 9 AVERAGE COST OF SOME INFERTILITY TREATMENTS

TABLE 10 SOME COMMON DRUG THERAPIES

TABLE 11 ASIA PACIFIC INFERTILITY TESTING AND TREATMENT MARKET BY END-USERS 2018-2026 (\$ MILLION)

TABLE 12 ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT MARKET BY COUNTRY 2018-2026 (\$MILLION)

## List Of Figures

### LIST OF FIGURES

FIGURE 1 ASIA PACIFIC INFERTILITY TESTING AND TREATMENT MARKET  
2018-2026 (\$ MILLION)

FIGURE 2 MAJOR FERTILITY TREATMENT DESTINATION RANKING

FIGURE 3 CLINICAL ALGORITHM FOR THE EVALUATION OF INFERTILE WOMAN

FIGURE 4 RATE OF MULTIPLE DELIVERIES

FIGURE 5 CAUSES OF INFERTILITY

FIGURE 6 CAUSES OF INFERTILITY BASED ON GENDER

FIGURE 7 CAUSES OF SPERM DNA FRAGMENTATION

FIGURE 8 GROWTH IN IVF CLINICS IN ASIA

FIGURE 9 CHINA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026  
(\$MILLION)

FIGURE 10 INDIA INFERTILITY TESTING AND TREATMENT MARKET 2018-2026  
(\$MILLION)

FIGURE 11 JAPAN INFERTILITY TESTING AND TREATMENT MARKET  
2018-2026(MILLION)

FIGURE 12 SOUTH KOREA INFERTILITY TESTING AND TREATMENT MARKET  
2018-2026 (MILLION)

FIGURE 13 MEDICAL TOURISM IN SOUTH KOREA (\$ MILLION)

FIGURE 14 REST OF ASIA-PACIFIC INFERTILITY TESTING AND TREATMENT  
MARKET 2018-2026 (\$ MILLION)

### COMPANIES MENTIONED

1. ANDROLOGY SOLUTIONS
2. ENDO PHARMACEUTICALS
3. PROGYNY
4. FERRING PHARMACEUTICALS
5. GENE A
6. HALOTECH DNA
7. IRVINE SCIENTIFIC
8. MERCK
9. ORIGIO
10. OVASCIENCE
11. VITROLIFE AB
12. THERMO FISHER SCIENTIFIC INC

13. THE COOPER COMPANIES, INC
14. QUEST DIAGNOSTIC
15. ESCO MICRO PTE. LTD.
16. ELUCIGENE
17. ALERE
18. CELMATRIX
19. VERITAS GENETICS
20. CLARITAS GENOMICS
21. ROCHE
22. LABCORP
23. AGILENT
24. INTEGRATED GENETICS
25. PHOSPHORUS DIAGNOSTICS
26. CENTOGENE
27. NATERA INC
28. ILLUMINA INC

## I would like to order

Product name: ASIA PACIFIC INFERTILITY TESTING AND TREATMENT MARKET FORECAST  
2018-2026

Product link: <https://marketpublishers.com/r/A57AC6784CAEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer  
Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click  
button on product page <https://marketpublishers.com/r/A57AC6784CAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form  
below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms  
& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below  
and fax the completed form to +44 20 7900 3970

